Epirus Biopharmaceuticals Company Profile (NASDAQ:EPRS)

About Epirus Biopharmaceuticals

Epirus Biopharmaceuticals logoEPIRUS Biopharmaceuticals, Inc. (Epirus) is a commercial-stage biopharmaceutical company. The Company is engaged in developing, manufacturing, and commercializing biosimilar therapeutics (biosimilars). The Company has a pipeline of operationally synergistic monoclonal antibodies (MAbs) in inflammation and immunology. The Company's lead product candidate, BOW015 is indicated for the treatment of various inflammatory diseases. The Company has launched BOW015 under the brand name, Infimab. The Company's products include BOW015, which contains infliximab; BOW050, which contains adalimumab; BOW070, which contains tocilizumab; BOW080, which contains eculizumab; BOW090, which contains ustekinumab, and BOW100, which contains golimumab.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EPRS
  • CUSIP:
Key Metrics:
  • Previous Close: $0.14
  • 50 Day Moving Average: $0.33
  • 200 Day Moving Average: $1.83
  • 52-Week Range: $0.08 - $6.76
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.29
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 2.52
Additional Links:
Companies Related to Epirus Biopharmaceuticals:

Analyst Ratings

Consensus Ratings for Epirus Biopharmaceuticals (NASDAQ:EPRS) (?)
Ratings Breakdown: 3 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $7.33 (5,138.10% upside)

Analysts' Ratings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Show:
DateFirmActionRatingPrice TargetDetails
5/15/2016Leerink SwannDowngradeOutperform -> Market PerformView Rating Details
5/11/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details
5/11/2016WedbushDowngradeOutperform -> Neutral$11.00 -> $2.00View Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/13/2016        
3/15/2016Q415($0.56)($0.63)ViewListenView Earnings Details
11/16/2015Q315($0.51)($0.59)$221.00 millionViewListenView Earnings Details
8/7/2015Q215($0.38)($0.65)ViewN/AView Earnings Details
5/12/2015Q1($0.43)($0.39)ViewN/AView Earnings Details
3/23/2015Q414($0.99)($0.80)ViewN/AView Earnings Details
11/10/2014($0.43)($1.28)ViewN/AView Earnings Details
8/20/2014($1.20)($1.52)ViewN/AView Earnings Details
5/9/2014Q114$0.20($0.15)$9.00 million$1.60 millionViewN/AView Earnings Details
3/13/2014($0.14)($0.29)ViewN/AView Earnings Details
11/4/2013Q313($0.50)($0.46)$3.66 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.07)($0.08)$2.91 million$3.89 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.07)($0.06)$3.44 million$3.70 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.08)($0.06)$3.12 million$3.67 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-0.49 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.66)($0.40)($0.53)
Q2 20162($0.52)($0.26)($0.39)
Q3 20162($0.43)($0.16)($0.30)
Q4 20162($0.27)($0.15)($0.21)
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.12)($0.12)($0.12)
Q3 20171($0.11)($0.11)($0.11)
Q4 20171($0.11)($0.11)($0.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/21/2015Robert TicktinGeneral CounselBuy3,000$3.72$11,160.00View SEC Filing  
12/17/2015Aurentz VincentInsiderBuy2,200$3.43$7,546.00View SEC Filing  
12/16/2015Amit MunshiCEOBuy8,270$2.80$23,156.00View SEC Filing  
12/15/2015Amit MunshiCEOBuy8,069$2.87$23,158.03View SEC Filing  
12/9/2015Amit MunshiCEOBuy13,190$4.07$53,683.30View SEC Filing  
12/9/2015Aurentz VincentInsiderBuy2,800$3.85$10,780.00View SEC Filing  
9/21/2015Amit MunshiCEOBuy10,000$6.19$61,900.00View SEC Filing  
9/18/2015Amit MunshiCEOBuy10,000$5.99$59,900.00View SEC Filing  
2/6/2015Montreux Equity Partners Iv LpMajor ShareholderSell167,316$5.00$836,580.00View SEC Filing  
2/4/2015Montreux Equity Partners Iv LpMajor ShareholderSell52,684$4.98$262,366.32View SEC Filing  
2/4/2015Scott M RocklageDirectorBuy400,000$5.00$2,000,000.00View SEC Filing  
1/26/2015Montreux Equity Partners Iv LpMajor ShareholderSell38,516$6.47$249,198.52View SEC Filing  
1/23/2015Montreux Equity Partners Iv LpMajor ShareholderSell22,530$6.29$141,713.70View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Epirus Biopharmaceuticals (NASDAQ:EPRS)
DateHeadline
News IconHC Stocks Summary= Galena Biopharma Inc (NASDAQ:GALE ... - share market updates (press release) (NASDAQ:EPRS)
sharemarketupdates.com - September 8 at 8:44 AM
News IconHC Stocks Assessment: Epirus Biopharmaceuticals Inc (NASDAQ:EPRS), AstraZeneca plc (ADR) (NYSE:AZN) - share market updates (press release) (NASDAQ:EPRS)
sharemarketupdates.com - August 18 at 10:12 PM
fortune.com logoEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) at $0.14: How much higher it can go - Review Fortune (NASDAQ:EPRS)
reviewfortune.com - August 4 at 5:06 PM
fortune.com logoEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Earns ... - Review Fortune (NASDAQ:EPRS)
reviewfortune.com - August 3 at 6:56 AM
istreetwire.com logoStocks To Watch: EPIRUS Biopharmaceuticals, Inc. (EPRS), Visa Inc. (V), Merck & Co. Inc. (MRK) - iStreetWire (NASDAQ:EPRS)
istreetwire.com - August 2 at 9:40 AM
biz.yahoo.com logoEPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul (NASDAQ:EPRS)
biz.yahoo.com - August 1 at 4:47 PM
fortune.com logoEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Insider Activities ... - Review Fortune (NASDAQ:EPRS)
reviewfortune.com - July 29 at 10:13 PM
investing.com logoU.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.01% (NASDAQ:EPRS)
www.investing.com - July 29 at 11:54 AM
News IconEye Catching Stock: EPIRUS Biopharmaceuticals, Inc. (NASDAQ ... - News Oracle (NASDAQ:EPRS)
www.newsoracle.com - July 28 at 3:34 PM
istreetwire.com logoStock's Trend Analysis Report: EPIRUS Biopharmaceuticals, Inc. (EPRS), American Airlines Group Inc. (AAL ... - iStreetWire (NASDAQ:EPRS)
istreetwire.com - July 26 at 4:53 PM
News IconAnalyst Buzz: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - News Oracle (NASDAQ:EPRS)
www.newsoracle.com - July 26 at 4:53 PM
streetupdates.com logoTraders Observable Stocks: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) , Merrimack Pharmaceuticals, Inc ... - Street Updates (NASDAQ:EPRS)
www.streetupdates.com - July 26 at 7:30 AM
streetinsider.com logoEPIRUS Biopharma (EPRS) Enters Livzon Satisfaction Amendment; Files for Chapter 7 Bankruptcy - StreetInsider.com (NASDAQ:EPRS)
www.streetinsider.com - July 25 at 10:22 PM
streetinsider.com logoEPIRUS Biopharma (EPRS) Enters Livzon Satisfaction Amendment; Files for Chapter 7 Bankruptcy (NASDAQ:EPRS)
www.streetinsider.com - July 25 at 4:53 PM
biz.yahoo.com logoEPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Bankruptcy or Receive (NASDAQ:EPRS)
biz.yahoo.com - July 25 at 11:32 AM
News IconEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:EPRS)
www.engelwooddaily.com - July 23 at 8:57 AM
fortune.com logoCurrent EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) PT Means Stock Is Worth Almost $2 - Review Fortune (NASDAQ:EPRS)
reviewfortune.com - July 21 at 5:01 PM
4-traders.com logoLion Biotechnologies : Biotechnology Stocks Technical Data -- EPIRUS Biopharma, Ampio Pharma, Spark Therapeutics, and Lion Biotechnologies (NASDAQ:EPRS)
www.4-traders.com - July 21 at 8:22 AM
News IconBiotechnology Stocks Technical Data -- EPIRUS Biopharma, Ampio Pharma, Spark Therapeutics, and Lion Biotechnologies (NASDAQ:EPRS)
www.kswo.com - July 21 at 8:22 AM
fiscalstandard.com logoBroker Outlook For EPIRUS Biopharmaceuticals, Inc. (EPRS) - Fiscal Standard (NASDAQ:EPRS)
www.fiscalstandard.com - July 20 at 7:14 AM
News IconEpirus Biopharmaceuticals Inc (NASDAQ:EPRS): Down, But Perhaps Not Out - Insider Financial (NASDAQ:EPRS)
www.insiderfinancial.com - July 18 at 4:59 PM
News IconHC Stocks Zone: Gilead Sciences, Inc. (NASDAQ:GILD), Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) - share market updates (press release) (NASDAQ:EPRS)
sharemarketupdates.com - July 15 at 7:29 AM
News IconNews review of 2 biotech stocks: Galena Biopharma, Inc. (NASDAQ:GALE), EPIRUS Biopharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:EPRS)
voiceregistrar.com - July 14 at 8:05 AM
fortune.com logoEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Earns Consensus Hold Rating - Review Fortune (NASDAQ:EPRS)
reviewfortune.com - July 14 at 8:05 AM
fortune.com logoWhich way EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) insiders are heading - Review Fortune (NASDAQ:EPRS)
reviewfortune.com - July 13 at 7:29 AM
fortune.com logoAnalysts: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) stock is worth $2 - Review Fortune (NASDAQ:EPRS)
reviewfortune.com - July 13 at 7:29 AM
News IconInvestor Catching Stock: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - News Oracle (NASDAQ:EPRS)
www.newsoracle.com - July 12 at 10:13 PM
istreetwire.com logo3 Notable Runners: EPIRUS Biopharmaceuticals, Inc. (EPRS), Johnson & Johnson (JNJ), Pandora Media, Inc. (P) - iStreetWire (NASDAQ:EPRS)
istreetwire.com - July 11 at 4:51 PM
News IconStock Rating Watch and Earnings Insight for EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - Press Telegraph (NASDAQ:EPRS)
presstelegraph.com - July 11 at 9:38 AM
News IconEpirus Biopharmaceuticals Inc (NASDAQ:EPRS) & Nokia Corp (ADR) (NYSE:NOK) Stocks on the Move - Money News (press release) (NASDAQ:EPRS)
www.newsismoney.com - July 11 at 9:38 AM
fiscalstandard.com logoNext Weeks Broker Price Targets For EPIRUS Biopharmaceuticals, Inc. (EPRS) - Fiscal Standard (NASDAQ:EPRS)
www.fiscalstandard.com - July 10 at 9:22 AM
News IconCan EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Improve on the Earnings Front? - Engelwood Daily (NASDAQ:EPRS)
www.engelwooddaily.com - July 9 at 8:20 AM
News IconCompany Stock Focus for EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS): Which Way Will Shares Head? - Press Telegraph (NASDAQ:EPRS)
presstelegraph.com - July 8 at 7:37 AM
News IconHC Stocks Highlights: Epirus Biopharmaceuticals Inc (NASDAQ:EPRS), AstraZeneca plc (ADR) (NYSE:AZN) - share market updates (press release) (NASDAQ:EPRS)
sharemarketupdates.com - July 7 at 4:54 PM
streetupdates.com logoSignificant Movements: Merck & Company, Inc. (NYSE:MRK) , EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - Street Updates (NASDAQ:EPRS)
www.streetupdates.com - July 7 at 7:22 AM
News IconEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Stock Update: Check on Ratings and Target Price - Telanagana Press (NASDAQ:EPRS)
telanaganapress.com - July 6 at 4:57 PM
News IconUnusual Volume Recap: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - Engelwood Daily (NASDAQ:EPRS)
www.engelwooddaily.com - July 6 at 4:57 PM
News IconHC Stocks Summary: Galena Biopharma Inc (NASDAQ:GALE), Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) - share market updates (press release) (NASDAQ:EPRS)
sharemarketupdates.com - July 6 at 4:57 PM
News IconWorthy Stock Update: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) - News Oracle (NASDAQ:EPRS)
www.newsoracle.com - July 6 at 4:57 PM
proactiveinvestors.co.uk logoDow Jones suffers triple-digit fall (NASDAQ:EPRS)
www.proactiveinvestors.co.uk - July 6 at 9:35 AM
investors.com logoUS stocks nurse losses as post-Brexit hurts oil prices (NASDAQ:EPRS)
www.proactiveinvestors.com - July 6 at 9:35 AM
benzinga.com logoStocks Hitting 52-Week Lows - Benzinga (NASDAQ:EPRS)
www.benzinga.com - July 5 at 4:45 PM
capitalcube.com logoETF’s with exposure to EPIRUS Biopharmaceuticals, Inc. : July 1, 2016 (NASDAQ:EPRS)
www.capitalcube.com - July 1 at 6:10 PM
biz.yahoo.com logoEPIRUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Mate (NASDAQ:EPRS)
biz.yahoo.com - July 1 at 5:23 PM
News IconEpirus Biopharmaceuticals Incorporated (NASDAQ:EPRS) Shorted Shares Increased By 15.46% - Press Telegraph (NASDAQ:EPRS)
presstelegraph.com - June 30 at 10:15 PM
News IconHow Analysts Rated Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) Last Week? - Press Telegraph (NASDAQ:EPRS)
presstelegraph.com - June 28 at 9:53 PM
ftsenews.co.uk logoNew Broker Ratings For EPIRUS Biopharmaceuticals, Inc. (EPRS) - FTSE News (NASDAQ:EPRS)
www.ftsenews.co.uk - June 28 at 9:53 PM
News IconEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Company Rating and Target Watch - Telanagana Press (NASDAQ:EPRS)
telanaganapress.com - June 28 at 9:53 PM
News IconHC Stocks Alerts: Gilead Sciences, Inc. (NASDAQ:GILD), Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) - share market updates (press release) (NASDAQ:EPRS)
sharemarketupdates.com - June 24 at 4:56 PM
News IconEPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:EPRS)
www.engelwooddaily.com - June 24 at 4:56 PM

Social

Epirus Biopharmaceuticals (NASDAQ:EPRS) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff